Loading…
Yes. One-time test, genetically determined, changes cardiovascular risk-stratification meaningfully.
Lp(a) is genetically stable, under-tested, and a meaningful CV-risk modifier when elevated.
Our read is Well Supported. The intervention clears a strong evidence base (84/100) with broad agreement among the voices we track (90% consensus). At $0/month and low effort, testing Lp(a) once in my life is one of the more defensible moves on this list — the burden of proof has largely been met.
Pulled the public claims about testing Lp(a) once in my life from proponents on file (a tracked voice) and weighed them against the more cautious voices in the field, then cross-checked each against the primary trial and cohort literature and the prevailing clinical guidance. We grade the claim against what the human evidence actually supports, not against how confidently it is stated.
Downside risk on testing Lp(a) once in my life is low at sensible doses, but low risk is not no risk: individual response varies, and a low-risk intervention is still only worth it if the benefit is real.
A well-powered trial showing the effect fails to hold up, or new safety surveillance that shifts the risk-benefit, would move this verdict.
Mechanistic and trial evidence converge on a real, replicable effect.
Mechanistic and trial evidence converge on a real, replicable effect.
The intervention improves the primary outcome at standard doses in healthy adults.
Mechanistic and trial evidence converge on a real, replicable effect.
Benefits hold across the populations where it's been tested.
Confounding and publication bias inflate the apparent benefit.
Animal-model results don't translate to the human protocol being recommended.
Most of the support comes from short or small studies.
The headline effect shrinks once you account for trial quality.